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Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is a fatal disease characterized by fibroblastic foci and progressive
scarring of the pulmonary parenchyma. IPF fibroblasts display increased proliferation and enhanced migration and
invasion, analogous to cancer cells. This transformation-like phenotype of fibroblasts plays an important role in the
development of pulmonary fibrosis, but the mechanism for this is not well understood.
Methods: In this study, we compared gene expression profiles in fibrotic lung tissues from IPF patients and normal
lung tissues from patients with primary spontaneous pneumothorax using a cDNA microarray to examine the
mechanisms involved in the pathogenesis of IPF. In a cDNA microarray, we found that USP13 was decreased in lung
tissues from patients with IPF, which was further confirmed by results from immunohistochemistry and western blot
assays. Then, we used RNA interference in MRC-5 cells to inhibit USP13 and evaluated its effects by western blot,
real-time RT-PCR, bromodeoxyuridine incorporation, and transwell assays. We also used co-immunoprecipitation and
immunofluorescence staining to identify the correlation between USP13 and PTEN in IPF.
Results: USP13 expression levels were markedly reduced in fibroblastic foci and primary IPF fibroblast lines.
The depletion of USP13 resulted in the transformation of fibroblasts into an aggressive phenotype with enhanced
proliferative, migratory, and invasive capacities. Additionally, USP13 interacted with PTEN and mediated PTEN
ubiquitination and degradation in lung fibroblasts.
Conclusions: Down-regulation of USP13 mediates PTEN protein loss and fibroblast phenotypic change, and
thereby plays a crucial role in IPF pathogenesis.
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Introduction
Idiopathic pulmonary fibrosis (IPF) is a progressive le-
thal interstitial lung disease of unknown etiology with
limited effective therapies [1]. It occurs more commonly
in elderly adults, and the median survival time is only
2–3 years from diagnosis, similar to many cancers [1, 2].
The pathogenic mechanisms of IPF remain unknown.
However, it has been generally accepted that IPF involves
aberrant wound healing in response to repetitive alveolar
epithelial micro-injuries, ultimately leading to the forma-
tion of scar tissue and a severe distortion of pulmonary
architecture [3]. Fibroblastic foci, the hallmark lesions of
IPF, are adjacent to sites of recent alveolar injury and indi-
cate current ongoing fibrogenesis [3, 4]. Their numbers
on surgical lung biopsies are correlated with disease pro-
gression in IPF patients [5, 6].
Fibroblastic foci are characterized by the exaggerated
accumulation of myofibroblasts and excessive deposition
of fibrillar collagens within the alveolar wall [7]. Myofi-
broblasts in fibroblastic foci, which express α-smooth
muscle actin (α-SMA) and have contractile properties,
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are responsible for excessive collagen deposition and ap-
pear to be resistant to apoptosis [8, 9]. Fibroblasts are the
major contributors to the myofibroblast population in fi-
broblastic foci [10]. Compared with cells from normal do-
nors, fibroblasts from IPF patients show more aggressive
biologic behaviors, including enhanced proliferation and
augmented migration and invasion [11–13], reminiscent
of cancer cells. Emerging evidence indicates that the
abnormal behaviors of fibroblasts in IPF are associated
with a variety of genetic alterations and the aberrant re-
activation of developmental signaling pathways, such as
hyaluronan synthase2 [13], focal adhesion kinase-related
non-kinase [14], and phosphatase and tensin homologue
deleted on chromosome 10 (PTEN) [15–17].
USP13 has been recognized as a deubiquitylase that
reverses PTEN polyubiquitylation and stabilizes PTEN
protein. Zhang and colleagues have demonstrated that
USP13 expression was reduced in human breast tumors
and that USP13 depletion could promote tumorigenesis
through the down-regulation of PTEN [18]. IPF is also
considered to be a neoproliferative lung disorder due to
its similarity to tumors [19]. However, little is known
about the role of USP13 in IPF. PTEN, as a tumor sup-
pressor, is involved in multiple cellular processes, such
as cell survival, apoptosis, adhesion, and cell migration/
invasion [20]. The loss of PTEN expression has been re-
ported to correlate with fibroproliferation in IPF by
White and colleagues [17]. Additionally, numerous stud-
ies have confirmed that PTEN expression is decreased in
fibroblasts isolated from IPF patients, which could ac-
count for the increased proliferative and migratory/inva-
sive capacities of IPF fibroblasts [15–17]. These findings
prompted us to explore the relationship between USP13
and PTEN in IPF pathogenesis.
In this study, our microarray assay revealed that
USP13 mRNA expression was decreased in IPF lung tis-
sues. Moreover, we also observed diminished USP13 ex-
pression in the fibroblastic foci of usual interstitial
pneumonia (UIP) lungs and in the primary lung fibro-
blasts isolated from IPF patients. We noticed that a
USP13 deficiency led to the transformation of fibroblasts
into an aggressive phenotype with enhanced prolifera-
tive, migratory, and invasive capacities. Additionally, we
found a correlation between USP13 loss and reduced
PTEN expression in IPF fibroblasts. Hence, our data
suggest that USP13, as a modulator regulating PTEN ex-
pression, is decreased in IPF fibroblasts and thereby con-
tributes to phenotypic changes in fibroblasts, which
might be essential events in IPF pathogenesis.
Materials and methods
Subjects and cells
Thirteen IPF patients with UIP confirmed by a surgical
lung biopsy were included in this study. All patients
were males with an average age of 51.08 ± 10.03 years.
The diagnosis of IPF was made according to the stan-
dards accepted by ATS/ERS/JRS/ALAT [1]. Five primary
IPF fibroblast lines were established from fresh lung tis-
sues obtained from five patients, who were a subset of
the 13 patients described above. Three primary normal
fibroblast lines were isolated from histologically proven
normal lung tissue from patients with primary spon-
taneous pneumothorax. Five normal, formalin-fixed,
paraffin-embedded (FFPE) lung specimens from ar-
chived tumor-adjacent healthy lung parenchyma of pa-
tients with non-small cell lung cancer were used for
immunohistochemistry. One normal human fetal pulmon-
ary fibroblast cell line (MRC-5) was purchased from
American Type Culture Collection (ATCC, Manassas, VA,
USA). This study was approved by the Ethics Committee
of Beijing Chao-Yang Hospital of Capital Medical
University, Beijing, China, and written informed con-
sent was obtained according to institutional guidelines
from all investigated subjects.
Primary fibroblast cell lines were generated by explant
culture and cultured in high glucose Dulbecco’s modified
Eagle’s medium (DMEM, HyClone, Logan, UT, USA)
containing 10 % fetal bovine serum (FBS, Invitrogen,
Carlsbad, CA, USA), 100 U/ml penicillin (Hyclone), and
100 mg/ml streptomycin (Hyclone), as previously de-
scribed [21]. Primary cells were characterized as fibro-
blasts, as shown in our previous reports [22, 23]. MRC-5
were maintained in Minimum Essential Medium (MEM)-
α (Invitrogen) with 10 % FBS (Invitrogen), 100 U/ml peni-
cillin (Hyclone), and 100 mg/ml streptomycin (Hyclone).
Under normoxic conditions, MRC-5 cells were cul-
tured in a humidified incubator (Thermo Scientific,
Waltham, MA, USA) at 37 °C in 95 % air (21 % O2) and
5 % CO2. A Heracell incubator (Thermo Scientific) filled
with nitrogen gas was used for hypoxic conditions (94 %
N2, 5 % CO2, and 1 % O2). All cell lines in this study
were used between passages five and eight.
Microarray experiment
The lung tissues that were used as the source of our pri-
mary fibroblast lines were also used for our microarray
experiment. They were obtained from five IPF patients
and three normal control subjects. Gene expression pro-
filing was performed according to the manufacturer’s
instructions using the GeneChip Human Transcriptome
Array 2.0 (Affymetrix, California, USA), which provided
probes for approximately 44,699 genes from the human
genome. Total RNA was isolated with TRIzol reagent
(Invitrogen) and purified using a RNeasy Mini Kit
(Qiagen, Hilden, Germany). The RNA concentration
was determined using a NanoDrop 2000 (Thermo
Scientific). The RNA purity and quality was assessed
by its A260/A280 ratio and agarose gel electrophoresis
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(Additional file 1: Figure S1). Biotinylated cDNA were
prepared from 250 ng total RNA by using an Ambion
WT Expression Kit (Affymetrix) according to the man-
ufacturer’s instructions. After labeling, 5.5 μg cDNA was
hybridized to the GeneChip Human Transcriptome Array
2.0. GeneChips were washed and stained in a GeneChip
Fluidics Station 450 (Affymetrix). GeneChips were then
scanned by using the Affymetrix GeneChip Command
Console Software that was installed in GeneChip Scanner
3000 7G (Affymetrix). Raw data were normalized at the
transcript level using the Robust Multi-Chip Average
(RMA) method [24]. A random variance model (RVM)
[25] t-test was applied to filter the differentially-
expressed genes for the control and experiment groups.
A p value <0.05 was considered to indicate a significant
difference. Complete microarray data were deposited in
the Gene Expression Omnibus website (Accession
number GSE72073).
Immunohistochemistry
Immunohistochemistry staining was performed on 4-
mm sections of FFPE lung specimens from 13 IPF
patients and five normal controls. Paraffinized sections
were deparaffinized in xylene and rehydrated through a
series of alcohol to water. Slides were stained with
hematoxylin and eosin (H&E) and viewed under a light
microscope. For immunohistochemistry, the tissue sec-
tions were deparaffinized and rehydrated as described
above. After a microwave treatment for 20 min in ethyl-
enediaminetetraacetic acid (EDTA) buffer and subse-
quent cooling, the endogenous peroxidase activity was
blocked by 0.3 % hydrogen peroxide in methanol for 15
min. After three washes followed by blocking in 5 %
skim milk in phosphate-buffered saline (PBS) for 30 min,
sections were incubated with antibodies against PTEN
(clone 6H2.1, Cascade Bioscience, Winchester, MA, USA),
USP13 (Abcam, Cambridge, MA, USA), and α-SMA
(R&D, Minneapolis, MN, USA) overnight at 4 °C. Sections
were incubated with horseradish peroxidase-conjugated
secondary antibodies and visualized using a 3, 3'-diamino-
benzidine (DAB) kit (Maixin Biotech, Fuzhou, China). All
slides were scanned using a Aperio ScanScope® AT (Leica,
Nussloch, Germany), and staining of USP13 was analyzed
with Aperio software.
Small interfering RNA (siRNA) transfection
MRC-5 cells were seeded in 6-well plates and incu-
bated overnight. USP13 siRNA (5 μM) and negative
control (NC) siRNA (5 μM) were separately mixed
with RNAiMAX transfection reagent (Invitrogen) ac-
cording to the manufacturer’s instructions. siRNA–
RNAiMAX complexes were added to MRC-5 cells
following two washes with serum-free medium. After
24 h, the transfection medium was replaced by culture
medium for another 24 h. A similar method with
PTEN siRNA was used for PTEN siRNA transfection.
USP13 siRNA #1 (s17129), USP13 siRNA #2 (s17130),
PTEN siRNA (s325), and negative control siRNA were
all Silence® Select siRNAs and were purchased from
Invitrogen (Carlsbad, CA, USA).
RNA purification, reverse transcription, and real-time
RT-PCR analysis
Total RNA was isolated using the TRIzol reagent
(Invitrogen) according to the manufacturer’s instruc-
tions. Reverse transcription was performed on 2 μg
total RNA with oligo (dT) primers in 25 μl reactions
using the Omniscript RT kit (Tiangen Biotech, Beijing,
China) according to the manufacturer’s instructions.
Real-time RT-PCR was carried out on an ABI PRISM®
7500 instrument (Applied Biosystems, Foster, CA,
USA) using SYBR-Green PCR reagents (Tiangen Bio-
tech) as previously described [22]. The primers used
were USP13-F: 5′-CCTGATGAACCAATTGATAGA
CC-3′; USP13-R: 5′-GTGATGATAGCTACGATTTC
CTC-3′, and PTEN-F: 5′-CGGCAGCAAATGTTTCA
G-3′; PTEN-R: 5′-AACTGGCAGGTAGAAGGCAAC
TC-3′. For each sample, β-actin was used for normalization
(β-actin-F: 5′-TGCTATCCAGGCTGTGCTAT-3′; β-actin-
R: 5′-AGTCCATCACGATGCCAGT-3′). The fold-
change of the target genes was calculated by using the
2-ΔΔCT method.
Protein extraction and western blot analysis
Total cell lysates were obtained using RIPA buffer
(Solarbio, Beijing, China) containing 1:100 phenyl-
methylsulfonyl fluoride and phosphatase inhibitors.
Cell lysates were resuspended in protein loading buf-
fer containing 5 % mercaptoethanol. The proteins
were separated by 10 % sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) (Bio-Rad,
Hercules, CA, USA) using a Mini-Protean electro-
phoresis module assembly (Bio-Rad) at 80 mV and
transferred to nitrocellulose membranes (Millipore,
Billerica, MA, USA) for 100 min using the Mini
Trans-Blot electrophoresis transfer cell (Bio-Rad) at
300 mA. The membranes were treated with
IRDyeTM800 (green)- or IRDyeTM700 (red)-conju-
gated affinity purified anti-rabbit or anti-mouse IgG
(LI-COR, Lincoln, NE, USA). Positive bands were vi-
sualized, and the intensity of the bands was evaluated
using a LI-COR Odyssey infrareddouble-fluorescence
imaging system (LI-COR). The primary antibodies
used were anti-human USP13 (ab99421, Abcam),
PTEN (ab32199, Abcam), and β-actin (CB100997M,
California Bioscience, Coachella, CA, USA).
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Immunofluorescence staining
MRC-5 cells seeded on glass slides were fixed in 90 %
cold ethanol, permeabilized by 0.1 % Triton X100 in
PBS, blocked with 5 % bovine serum albumin (BSA), and
incubated with anti-PTEN (26H9, #9556, Cell Signaling
Technology, Danvers, MA, USA) or anti-USP13 (ab99421,
Abcam) overnight at 4 °C. Cells were washed and incu-
bated with Alexa Fluor® 594-conjugated goat anti-mouse/
488-conjugated goat anti-rabbit secondary antibodies
(Jackson ImmunoResearch, West Grove, PA, USA) for 50
min in the dark. Cells were washed three times, mounted
with 4'6-diamidino-2-phenylindole (DAPI)-containing
mounting media (ZSGB-BIO, Beijing, China), and visual-
ized using a confocal laser scanning microscope (Leica
Microsystems, Wetzlar, Hesse, Germany).
Bromodeoxyuridine (BrdU) cell proliferation assay
MRC-5 cells were seeded on glass slides in 24-well
plates and transfected with PTEN siRNA or NC
siRNA for 24 h without FBS, followed by incubation
with MEM-α containing 10 % FBS and antibodies
for another 24 h. BrdU incorporation was measured
using a BrdU labeling and detection kit (Roche,
Mannheim, Germany) in accordance with the manu-
facturer’s protocol. Briefly, MRC-5 cells were labeled
with 10 μM BrdU during an incubation of 50 min.
After labeling, the cells were washed three times,
fixed, and treated with mouse anti-BrdU monoclonal
antibody for 30 min at 37 °C, followed by an anti-
mouse-Ig-fluorescein working solution. Cells were
washed three times and mounted with DAPI-containing
mounting media (ZSGB-BIO, Beijing, China). Cellular
proliferation was assessed by the percent of BrdU-staining
cells in nuclear-positive cells in the same microscopic vis-
ual field. Experiments were performed three independent
times. The BrdU positive rate was evaluated by counting
five different microscopic fields per time point.
Migration/invasion assay
Migration assays were performed using 8-μm pore trans-
well chambers (Millipore). In invasion assays, transwell
chambers with 8-μm pores were coated with 30 μl of
matrigel (BD Biosciences, San Diego, CA, USA) gel mix-
ture (1:5 in MEM-α containing 0.1 % FBS), and allowed
to solidify for 1 h at 37 °C.
Briefly, cells were transfected with PTEN siRNA or
NC siRNA for 24 h prior to detachment with 0.125 %
trypsin (Hyclone). A total of 2 × 104 cells were resus-
pended in MEM-α media containing 0.1 % FBS and
added to the upper chamber. MEM-α media contain-
ing 10 % FBS was added to the lower chamber. Cell
viability was assessed by crystal violet staining and
microscopic evaluation.
Immunoprecipitation
Whole cell lysates were obtained using lysis buffer
(50 mM HEPES at pH 8.0, 150 mM NaCl, 0.5 % Tri-
ton X-100, 0.5 % NP-40, 1 mM DTT, cocktail inhibi-
ter, and 10 % glycerol) and mixed with pre-cleared
protein A/G agarose beads (Santa Cruz Biotechnology,
CA, USA) for 2 h. The lysates were then immunoprecipi-
tated with the indicated antibodies and protein A/G beads
overnight at 4 °C. Beads were washed four times with lysis
buffer and boiled in 2× loading buffer. Protein samples
were resolved by 8 % SDS-PAGE (Bio-Rad, Hercules, CA,
USA) and transferred onto a polyvinylidene difluoride
membrane (Millipore, Billerica, MA, USA), and mem-
branes were probed with the indicated antibodies. The
primary antibodies used were human USP13 (ab99421,
Abcam) and PTEN (26H9, #9556, Cell Signaling
Technology). Reactive proteins were detected by the
ECL Chemiluminescence System (Millipore).
Ubiquitination assay
Cells were transfected with USP13 siRNA and treated
with 10 μM proteasome inhibitor (MG-132, Millipore)
for 6 h before harvest or stimulated with hypoxia for 48 h,
as indicated. Whole cells were lysed in lysis buffer (50
mM Tris–HCl at pH 8.0, 150 mM NaCl, 5 mM DTT, and
10 % glycerol). After boiling for 5 min, lysates were diluted
100-fold with cold lysis buffer containing an inhibitor
cocktail. After immunoprecipitation with the indicated
antibodies, the immunoprecipitates were resolved by 8 %
SDS-PAGE (Bio-Rad) and transferred onto a polyvinyli-
dene difluoride membrane (Millipore). The blot was
blocked in 5 % BSA and probed with an anti-ubiquitin
antibody (ab7780, Abcam) according to the manufac-
turer’s instructions. Reactive proteins were detected by the
ECL Chemiluminescence System (Millipore).
Statistical analysis
Data are expressed as the mean ± SEM where applic-
able. We assessed differences in measured variables
using the unpaired/paired two-sided Student’s t-test
or Mann–Whitney test for nonparametric data. p <0.05
was considered statistically significant. SPSS 16.0 (SPSS
Inc., Chicago, IL, USA) and GraphPad Prism 5.0
(Graphpad Software, La Jolla, CA, USA) were used
for statistical analysis and graph creation.
Results
Decreased USP13 expression in tissues from IPF patients
To identify gene expression profiles involved in the
pathogenesis of IPF, we performed a comparative cDNA
microarray analysis of the lung tissues from IPF patients
(n = 5) and control subjects (n = 3). We found 1476
differentially-expressed genes between the two groups of
patients at a significance threshold of p <0.05 (Fig. 1a).
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Fig. 1 (See legend on next page.)
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Given the known role of USP13 in the deubiquitylation
and stabilization of PTEN, we were particularly inter-
ested in the down-regulation of USP13 in IPF (Fold-
change = 0.78 and p = 0.017 in microarray data, real-time
RT-PCR validation in Fig. 1b). To further evaluate
USP13 expression in IPF, we first performed immunohis-
tochemistry on surgical lung biopsy specimens from 13
IPF patients with a pathologic diagnosis of UIP. In 11
out of 13 IPF patients, USP13 staining was diminished
or absent in fibroblastic foci compared with that in the
overlying epithelial layers (Fig. 1c and d). We then exam-
ined USP13 expression in primary human lung fibroblast
lines isolated from fresh lung tissues of five IPF patients
and three normal lung tissues. As shown in Fig. 2,
USP13 protein and mRNA levels were visibly decreased
in primary IPF fibroblast lines compared with those in
primary normal fibroblast lines.
USP13-deficient fibroblasts display an aggressive
phenotype
In view of the striking difference in the level of USP13
expression between IPF and normal lung fibroblasts, we
investigated the effects of USP13 loss on the phenotype
of fibroblasts, specifically their proliferative capacity and
migratory/invasive capacity.
We knocked down USP13 expression in normal lung
fibroblasts (MRC-5 cells) by using siRNA interference.
As shown in Fig. 3, two USP13 siRNA (USP3si #1 and
USP13si #2, 5 μM) were tested and both of them signifi-
cantly down-regulated USP13 mRNA and protein ex-
pression levels at 48 h post-transfection, compared with
the negative control siRNA (NCsi). Therefore, either of
them could be used in the subsequent experiments,
MRC-5 cells were treated with a siRNA against USP13
or a negative control for 48 h, respectively named MRC-
5USP13si cells and MRC-5NCsi cells.
We next measured cell proliferation using BrdU in-
corporation assays in MRC-5USP13si cells and MRC-5NCsi
cells. As shown in Fig. 4a, USP13 deficiency significantly
increased fibroblast proliferation.
We then assessed the effects of USP13 reduction on
the migratory and invasive capacities of fibroblasts. After
transfection with USP13 siRNA or NC siRNA for 24 h,
equal numbers of fibroblasts were loaded into a trans-
well chamber with or without matrigel. USP13 deficiency
also dramatically promoted the invasive and migratory
capacity of normal lung fibroblasts in vitro (Fig. 4b).
USP13 deficiency accounts for the decreased PTEN
protein expression in IPF fibroblasts
Considering that loss of PTEN contributed to fibroblasts
phenotypic changes and USP13 interacted with PTEN
and functioned as a deubiquitylase in epithelial cells, we
subsequently sought to determine whether USP13 defi-
ciency is responsible for the low PTEN expression ob-
served in IPF fibroblasts.
Consistent with previous reports, we discovered that
PTEN protein expression was markedly reduced in
the IPF fibroblast lines, compared with that in normal
fibroblasts, but no significant difference in the level
(See figure on previous page.)
Fig. 1 USP13 expression levels in IPF lung tissues. a Gene expression profiles of fibrotic lung tissue from IPF patients (n = 5) and of normal lung
tissues from primary spontaneous pneumothorax patients (n = 3). Red areas indicate increased gene expression relative to the mean of all samples,
and green areas indicate decreased gene expression. Each column represents one patient, and each row represents one gene. b Graph of USP13
mRNA levels in representative samples. USP13 mRNA expression levels of representative samples were verified by real-time RT-PCR. β-actin was used
as a control. c USP13 expression in IPF lung tissue fibroblastic foci. Representative serial lung sections from one patient with IPF and one normal control
were stained for H&E (a, b, c) and USP13 (d, e, f). A fibrotic focus is indicated with a black box in (b) and (e). High magnification of the boxed region in
(c) and (f). (a, b, d, e) original magnification × 100; (c, f) original magnification × 400. d Relative intensity analysis of USP13 staining in IPF lung
tissue fibroblastic foci (n = 13) and normal control (n = 5). The quantitative data were expressed as the ratio of stained areas in myofibroblasts
within FF (IPF) or mesenchymal cells (Normal) to the overlying epithelial cells. Staining intensity was represented by the percentage of positive-staining
cells in the indicated tissues. Error bars indicate the mean ± SEM. *p <0.05, ***p <0.001
Fig. 2 USP13 expression levels in primary fibroblast lines from IPF
patients. a Graph of USP13 mRNA expression in primary IPF
fibroblast lines (n = 5) and primary normal fibroblast lines (n = 3).
USP13 mRNA expression levels were verified by real-time RT-PCR.
b Protein expression levels of USP13 in the primary fibroblast lines were
shown by western blot. c Graph of USP13 protein levels in
representative primary fibroblast lines was shown. Relative intensity
analysis of USP13 protein expression levels were assessed by
fold-change of target protein/β-actin with standardization by setting
the “normal control #1” as 1. β-actin was used as a control in both
western blot and real-time RT-PCR assays. Error bars indicate the
mean ± SEM. *p <0.05, **p <0.01
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of PTEN mRNA expression was found between these
two groups (Fig. 5a).
We then examined the effects of USP13 deficiency on
PTEN protein and mRNA levels. As shown in Fig. 5b
and c, compared with MRC-5NCsi cells, MRC-5USP13si
displayed a marked decrease in PTEN protein levels with
no obvious change in their mRNA levels. Additionally,
our data showed that the suppression of PTEN by
siRNA did not lead to a reduction in USP13 expression
(Fig. 5d). These data suggest that USP13 regulates the
PTEN protein expression level, but PTEN does not
affect USP13 expression.
Next, we performed a co-immunoprecipitation with
whole cell lysates from untreated MRC-5 cells and
found an association of PTEN with USP13 (Fig. 6a). To
further validate the interaction between USP13 and
PTEN, an immunofluorescent confocal microscopic
analysis was conducted. Our results (Fig. 6b) showed a
co-localization of USP13 and PTEN in lung fibroblasts.
Additionally, we noticed that in fibroblasts, the loss of
USP13 down-regulated PTEN protein expression by in-
creasing PTEN ubiquitination. As shown in Fig. 6c,
compared with MRC-5NCsi cells, in whole cell lysates of
MRC-5USP13si cells, the expression of ubiquitinated
Fig. 3 Knockdown of USP13 through RNA interference. MRC-5 cells were transfected with negative control siRNA (NCsi) or two different USP13
siRNAs (USP13si #1 and #2) for 24 h or 48 h. a Graph of USP13 mRNA levels at both 24 h and 48 h in USP13 siRNA-treated cells. b Graph of
USP13 protein levels at 24 h or 48 h after USP13 siRNA transfection. c Protein expression levels of representative samples are shown. Error
bars indicate the mean ± SEM. *p <0.05, **p <0.01
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PTEN was enhanced while that of total PTEN protein
was decreased.
To further confirm the effects of USP13 loss on
PTEN expression, we performed immunocellularchemical
staining of USP13 and PTEN in MRC-5USP13si cells and
MRC-5NCsi cells. We observed that USP13 deficiency led
to a marked reduction in the level of PTEN protein ex-
pression (Fig. 6d).
Additionally, we performed immunohistochemical stain-
ing of PTEN in the lung tissue samples of 13 IPF patients
to further validate the correlation between USP13 loss
and reduced PTEN expression in IPF fibroblasts. In the
same 11 IPF patients, we observed a weaker staining of
both USP13 and PTEN and a stronger staining of α-SMA
in myofibroblasts within fibroblastic foci, compared with
those in the overlying epithelial cells (Fig. 6e).
Collectively, these data revealed a strong correlation
between USP13 deficiency and down-regulated PTEN
expression in IPF fibroblasts.
Hypoxia-reduced expression of USP13 correlates with
PTEN protein loss
Hypoxia has been recognized as a prominent microen-
vironmental factor in tissue injury, normal wound heal-
ing, and fibrosis [26]. We exposed MRC-5 cells to
normoxic (21 % O2) or hypoxic (1 % O2) conditions for
48 h and discovered that hypoxia induced a significant
decrease in the level of USP13 expression, coinciding
with a reduction in the level of PTEN protein expres-
sion, as well as an increase in the level of PTEN ubiqui-
tination (Fig. 7). These findings strongly suggest that
under hypoxic conditions, USP13 down-regulation and
low PTEN expression exist in lung fibroblasts.
Discussion
It is generally accepted that IPF involves an aberrant
would healing in response to repetitive lung injury, and
ultimately results in fibrosis [3]. The fibroblast is consid-
ered to be the classical cell type involved in the patho-
genesis of IPF and the major contributor to the pool of
myofibroblasts in fibroblastic foci [10]. A prerequisite
for this consideration is the migration of IPF fibroblasts
to the site of injury and their subsequent proliferation
and transformation [27]. In this study, we found dimin-
ished USP13 mainly in IPF fibroblasts, which contrib-
uted to fibroblast migration, invasion, and proliferation.
Our observation suggests that USP13, serving as an im-
portant regulator of fibroblast biologic behaviors, plays a
critical role in the pathogenesis of IPF.
Recently, mounting evidence supports the existence
of similarities between IPF and cancer in both patho-
genesis and biology [19, 28, 29]. The critical role of
PTEN in the pathogenesis of IPF has drawn attention
due to its role as a tumor suppressor [16, 30]. PTEN
protein, as a dual-specificity lipid and protein phos-
phatase, antagonizes the phosphoinositide 3-kinase
(PI3K)-Akt signal pathway and dephosphorylates focal
adhesion kinase (FAK), which has been implicated in car-
cinogenesis and in the pathogenesis of IPF [17, 31, 32]. It
has been shown that decreased PTEN expression or ac-
tivity is associated with pathological phenotypes of IPF
fibroblasts [17, 33]. Xia has demonstrated that low
Fig. 4 Proliferative, migratory, and invasive capacity of fibroblasts following the down-regulation of USP13. a Proliferation of cells with USP13
deficiency. At 48 h after transfection with USP13 siRNA (USP13si) or NC siRNA (NCsi), MRC-5 cell proliferation was assessed by a BrdU incorporation
assay. The proliferating cells that recently underwent DNA synthesis were labeled with BrdU (green), and total nuclei were visualized by DAPI
(blue) staining. % BrdU: Percent of BrdU+ cells within the siRNA-treated MRC-5 cell population. Error bars indicate the mean ± SEM. ***p <0.001.
b The migratory and invasive capacity of fibroblasts with decreased USP13. Twenty-four hours after transfection with either USP13 siRNA or NC
siRNA, equal numbers of fibroblasts were loaded into transwell chambers with or without matrigel. Images of migratory fibroblasts (top panel)
and invasive fibroblasts (bottom panel) are shown from a crystal violet staining assay at different time points, as indicated
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caveolin-1 expression led to diminished membrane
PTEN levels and low PTEN phosphatase activity in IPF
fibroblasts [15]. However, the mechanisms responsible
for this decreased PTEN expression in IPF fibroblasts
have not been well established. Our data show that
PTEN protein, but not PTEN mRNA, levels were
decreased in IPF fibroblasts, strongly implying that
PTEN down-regulation is due to posttranslational
modification. It was reported that USP13 acted as a
deubiquitylase of PTEN in breast cancer [18]. Inte-
restingly, we found that USP13 interacted with PTEN
in fibroblasts and regulated PTEN ubiquitination and
degradation, supporting the idea that IPF is a cancer-
like disease. Consistently, both USP13 and PTEN
expression were diminished in myofibroblasts within
fibroblastic foci in 11 out of 13 (84.6 %) IPF patients.
These data confirm a strong correlation between
USP13 and PTEN in IPF. As a deubiquitylase, USP13
has been reported to cooperate with gp87 to promote
endoplasmic reticulum (ER)-associated degradation
(ERAD) [34] and to interact with Siah2, subsequently
regulating its activity [35]. Hence, it is possible that
USP13 contributes to the pathogenesis of IPF through
different pathways. Further studies are needed to ex-
plore this possibility.
Hypoxia is an important factor in various lung patho-
logical processes, including pulmonary fibrosis [36].
Hypoxia has been shown to enhance fibroblast prolifer-
ation with an increased production of extracellular
matrix [37, 38]. Our data demonstrate that when ex-
posed to hypoxia, the expression levels of both USP13
and PTEN were down-regulated in fibroblasts. This
Fig. 5 The PTEN protein level in UPS13-deficient cells. a PTEN protein and mRNA levels in primary IPF fibroblasts. Relative intensity analysis of
PTEN protein expression levels in primary IPF fibroblast lines (n = 5) and primary normal fibroblast lines (n = 3) were assessed by the fold-change
of target protein/β-actin with standardization by setting the “normal control #1” as 1. PTEN mRNA expression was measured by real-time RT-PCR,
and the fold-change was calculated by using the 2-ΔΔCT method. b, c MRC-5 cells were transfected with USP13 siRNA (USP13si) or NC siRNA (NCsi)
for 48 h and PTEN protein (b) and mRNA (c) levels were measured by western blot and real-time RT-PCR. d MRC-5 cells were transfected with
PTEN siRNA (PTENsi) or NCsi for 48 h, and USP13 protein expression was assessed by western blot. β-actin was used as a control in both the west-
ern blot and real-time RT-PCR assays. Error bars indicate the mean ± SEM. *p <0.05, **p <0.01
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Fig. 6 Levels of PTEN ubiquitination and degradation in USP13-deficient lung fibroblasts. a Endogenous USP13 was immunoprecipitated from
MRC-5 whole cell lysates and immunoblotted with antibodies against USP13 and PTEN (left panel), while endogenous PTEN was immunoprecipitated
from MRC-5 whole cell lysates and immunoblotted with antibodies against PTEN and USP13 (right panel). b Co-localization of USP13 and PTEN. PTEN
(red) and USP13 (green) were labeled by immunofluorescence staining of MRC-5 cells. The right panel shows the overlay (merge) of PTEN,
USP13, and nuclear DAPI staining (blue) in the same field to determine co-localization. Scale bar, 20 μm. c At 42 h after transfection with
USP13 siRNA or NC siRNA, we added MG-132 (10 μM) for 6 h and harvested whole cell lysates. PTEN and ubiquitinated PTEN (Ub-PTEN) were
assessed by immunoprecipitation and western blot. β-actin was used as a loading control. d Immunofluorescence staining of PTEN (red) and
USP13 (green) in MRC-5 cells transfected with USP13 siRNA (USP13si) or negative control siRNA (NCsi) for 48 h. Nuclei were visualized by DAPI
(blue) staining. Scale bar, 20 μm. (a–d) Data are representative of at least three independent experiments. e Representative serial lung sections
from one IPF patient were stained for (a) H&E, (b) α-SMA, (c) PTEN, and (d) USP13. Images are representative of staining performed on samples
from 11 individuals with IPF. Scale bar, 100 μm
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finding points to a new regulatory mechanism of fibro-
blast phenotypes under hypoxic conditions. Furthermore,
the finding of a diminished level of USP13 concurrent
with a low PTEN protein level in myofibroblasts within fi-
broblastic foci or in fibroblasts maintained under hypoxia
implies that the loss of USP13 is a key mechanism respon-
sible for PTEN down-regulation in IPF fibroblasts.
In conclusion, USP13 was down-regulated in lung tis-
sues from patients with IPF, especially in fibrotic foci, and
in primary IPF fibroblast lines. USP13 deficiency, via
down-regulating the PTEN protein level and subsequently
mediating the phenotypic changes of lung fibroblasts, con-
tributes to the pathogenesis of IPF. Thus, USP13 may be a
novel potential target for intervention in lung fibrosis.
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